Moreover, compound 1 counteracted two critical transcription factors HoxA9 and Myc in MLL1-r leukemia: treatment with compound 1 reversed expression patterns of HoxA9-regulated genes [49] (Fig. 5d.5 and 6). Here, KMT2A is linked to leukemia.